Enrolling By InvitationNCT06605105
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
Researchers are studying CYB003 to find out how it affects depression symptoms in people with depression.
Medication studyAges 18–85Multiple countries
Understand this study
What is this study about?
Researchers are studying CYB003 to find out how it affects depression symptoms in people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria apply.
- Listed locations
- Phoenix and 48 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 18, 2025
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 468
- Sponsor
- Cybin IRL Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, United Kingdom, ...
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT06605105
- Official title
Show the full official title
A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Phoenix, United States · Glendale, United States · La Jolla, United States
39 more locations
- Los Angeles, United States
- Oceanside, United States
- San Francisco, United States
- San Juan Capistrano, United States
- Denver, United States
- Evergreen, United States
- Hollywood, United States
- Jacksonville, United States
- Lady Lake, United States
- Lauderhill, United States
- Maitland, United States
- Orlando, United States
- Atlanta, United States
- Savannah, United States
- Chicago, United States
- Skokie, United States
- Rockville, United States
- Boston, United States
- Springfield, United States
- Watertown, United States
- Eden Prairie, United States
- Las Vegas, United States
- Princeton, United States
- Toms River, United States
- New York, United States
- The Bronx, United States
- Canton, United States
- Philadelphia, United States
- Memphis, United States
- DeSoto, United States
- Houston, United States
- Draper, United States
- Maroochydore, Australia
- Melbourne, Australia
- Notting Hill, Australia
- Athens, Greece
- Thessaloniki, Greece
- Bydgoszcz, Poland
- Reading, United Kingdom
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are studying CYB003 to find out how it affects depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Cybin IRL Limited.
Does this study involve medication?
Yes. The study involves medication, including CYB003.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
